Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.

PMID: 22402756
Journal: GENETICS IN MEDICINE
Year: 2012
Reference: Genet Med. 2012 Jul;14(7):670-80. doi: 10.1038/gim.2012.18. Epub 2012 Mar 8.
Impact factor:
Publication type: Paper in international publication
Authors: Backes, Floor J; Balmana, Judith; Casey, Graham; Cohn, David E; de la Chapelle, Albert; Haile, Robert; Hampel, Heather; Hopper, John L; Jenkins, Mark A; Kastrinos, Fay et al.
DOI: 10.1038/gim.2012.18

Perioperative use of prothrombin complex concentrates.

PMID: 22357373
Journal: Minerva Anestesiologica
Year: 2012
Reference: Minerva Anestesiol. 2012 Mar;78(3):358-68.
Impact factor: 2.656
Publication type: Review in international publication
Authors: Colomina, M J, Diez Lobo, A, Garutti, I, Gomez-Luque, A, Llau, J V, Pita, E et al.
DOI:

Perioperative use of prothrombin complex concentrates.

PMID: 22357373
Journal: Minerva Anestesiologica
Year: 2012
Reference: Minerva Anestesiol. 2012 Mar;78(3):358-68.
Impact factor:
Publication type: Review in international publication
Authors: Colomina, M J; Diez Lobo, A; Garutti, I; Gomez-Luque, A; Llau, J V; Pita, E et al.
DOI:

Persistent Angina Pectoris, Cardiac Mortality and Myocardial Infarction During a 12 Year Follow-Up in 273 Variant Angina Patients Without Significant Fixed Coronary Stenosis.

PMID: 22835410
Journal: AMERICAN JOURNAL OF CARDIOLOGY
Year: 2012
Reference: Am J Cardiol. 2012 Nov 1;110(9):1249-55. doi: 10.1016/j.amjcard.2012.06.026. Epub 2012 Jul 25.
Impact factor: 3.368
Publication type: Paper in international publication
Authors: Figueras, Jaume, Domingo, Enric, Ferreira, Ignacio, Lidon, Rosa Maria, Garcia-Dorado, David et al.
DOI: 10.1016/j.amjcard.2012.06.026

Persistent Angina Pectoris, Cardiac Mortality and Myocardial Infarction During a 12 Year Follow-Up in 273 Variant Angina Patients Without Significant Fixed Coronary Stenosis.

PMID: 22835410
Journal: AMERICAN JOURNAL OF CARDIOLOGY
Year: 2012
Reference: Am J Cardiol. 2012 Nov 1;110(9):1249-55. doi: 10.1016/j.amjcard.2012.06.026. Epub 2012 Jul 25.
Impact factor:
Publication type: Paper in international publication
Authors: Domingo, Enric; Ferreira, Ignacio; Figueras, Jaume; Garcia-Dorado, David; Lidon, Rosa Maria et al.
DOI: 10.1016/j.amjcard.2012.06.026

Personality profile of adult ADHD: The alternative five factor model.

PMID: 22386569
Journal: PSYCHIATRY RESEARCH
Year: 2012
Reference: Psychiatry Res. 2012 Jun 30;198(1):130-4. doi: 10.1016/j.psychres.2011.11.006. Epub 2012 Mar 3.
Impact factor: 2.524
Publication type: Paper in international publication
Authors: , , , , , , , , et al.
DOI: 10.1016/j.psychres.2011.11.006

Personality profile of adult ADHD: The alternative five factor model.

PMID: 22386569
Journal: PSYCHIATRY RESEARCH
Year: 2012
Reference: Psychiatry Res. 2012 Jun 30;198(1):130-4. doi: 10.1016/j.psychres.2011.11.006. Epub 2012 Mar 3.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; et al.
DOI: 10.1016/j.psychres.2011.11.006

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

PMID: 22393084
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2012
Reference: J Clin Oncol. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. Epub 2012 Mar 5.
Impact factor: 18.372
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1200/JCO.2011.37.4207

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

PMID: 22393084
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2012
Reference: J Clin Oncol. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. Epub 2012 Mar 5.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1200/JCO.2011.37.4207

Phase 1 Pharmacokinetic/Pharmacodynamic Study of MLN8237 - An Investigational, Oral, Selective Aurora A Kinase Inhibitor - In Patients With Advanced Solid Tumors.

PMID: 22753585
Journal: CLINICAL CANCER RESEARCH
Year: 2012
Reference: Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2.
Impact factor: 7.742
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1158/1078-0432.CCR-12-0571

Phase 1 Pharmacokinetic/Pharmacodynamic Study of MLN8237 - An Investigational, Oral, Selective Aurora A Kinase Inhibitor - In Patients With Advanced Solid Tumors.

PMID: 22753585
Journal: CLINICAL CANCER RESEARCH
Year: 2012
Reference: Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1158/1078-0432.CCR-12-0571

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 22162589
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2012
Reference: J Clin Oncol. 2012 Jan 20;30(3):282-90. Epub 2011 Dec 12.
Impact factor: 18.372
Publication type: Paper in international publication
Authors: Bendell, Johanna C, Rodon, Jordi, Burris, Howard A, de Jonge, Maja, Verweij, Jaap, Birle, Diana, Demanse, David, De Buck, Stefan S, Ru, Qinhua C, Peters, Malte et al.
DOI: 10.1200/JCO.2011.36.1360

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

PMID: 22162589
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2012
Reference: J Clin Oncol. 2012 Jan 20;30(3):282-90. Epub 2011 Dec 12.
Impact factor:
Publication type: Paper in international publication
Authors: Baselga, Jose; Bendell, Johanna C; Birle, Diana; Burris, Howard A; De Buck, Stefan S; de Jonge, Maja; Demanse, David; Goldbrunner, Michael; Peters, Malte; Rodon, Jordi et al.
DOI: 10.1200/JCO.2011.36.1360

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors.

PMID: 22382883
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2012
Reference: Cancer Chemother Pharmacol. 2012 Jun;69(6):1467-75. doi: 10.1007/s00280-012-1856-4. Epub 2012 Mar 1.
Impact factor: 2.833
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1007/s00280-012-1856-4

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors.

PMID: 22382883
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2012
Reference: Cancer Chemother Pharmacol. 2012 Jun;69(6):1467-75. doi: 10.1007/s00280-012-1856-4. Epub 2012 Mar 1.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1007/s00280-012-1856-4

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

PMID: 22357447
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 Sep;23(9):2399-408. doi: 10.1093/annonc/mds011. Epub 2012 Feb 22.
Impact factor: 6.425
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1093/annonc/mds011

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

PMID: 32018716
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 Sep;23(9):2399-2408. doi: 10.1093/annonc/mds011. Epub 2019 Dec 4.
Impact factor: 6.425
Publication type: Paper in international publication
Authors: Markman, B, Tabernero, J, Siu, L, Chen, L C, Mita, M, Melendez Cuero, M, Stutvoet, S, Birle, D, Anak, O, Hackl, W et al.
DOI: 10.1093/annonc/mds011

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

PMID: 22357447
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 Sep;23(9):2399-408. doi: 10.1093/annonc/mds011. Epub 2012 Feb 22.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1093/annonc/mds011

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

PMID: 32018716
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 Sep;23(9):2399-2408. doi: 10.1093/annonc/mds011. Epub 2019 Dec 4.
Impact factor:
Publication type: Paper in international publication
Authors: Anak, O; Baselga, J; Birle, D; Chen, L C; Hackl, W; Krop, I; Markman, B; Melendez Cuero, M; Mita, M; Shapiro, G I et al.
DOI: 10.1093/annonc/mds011

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

PMID: 21576284
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 Feb;23(2):463-71. Epub 2011 May 16.
Impact factor: 6.425
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1093/annonc/mdr137

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

PMID: 21576284
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 Feb;23(2):463-71. Epub 2011 May 16.
Impact factor:
Publication type: Paper in international publication
Authors: ; ; ; ; ; ; ; ; ; et al.
DOI: 10.1093/annonc/mdr137

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

PMID: 32018583
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 May;23(5):1241-1249. doi: 10.1093/annonc/mdr380. Epub 2019 Dec 4.
Impact factor: 6.425
Publication type: Paper in international publication
Authors: de Bono, J S, Molife, L R, Sonpavde, G, Maroto, J P, Calvo, E, Cartwright, T H, Loesch, D M, Feit, K, Das, A, Zang, E A et al.
DOI: 10.1093/annonc/mdr380

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

PMID: 21903605
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 May;23(5):1241-1249. doi: 10.1093/annonc/mdr380. Epub 2011 Sep 7.
Impact factor: 6.425
Publication type: Paper in international publication
Authors: de Bono, J S, Molife, L R, Sonpavde, G, Maroto, J P, Calvo, E, Cartwright, T H, Loesch, D M, Feit, K, Das, A, Zang, E A et al.
DOI: 10.1093/annonc/mdr380

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

PMID: 32018583
Journal: ANNALS OF ONCOLOGY
Year: 2012
Reference: Ann Oncol. 2012 May;23(5):1241-1249. doi: 10.1093/annonc/mdr380. Epub 2019 Dec 4.
Impact factor:
Publication type: Paper in international publication
Authors: Agoulnik, S; Calvo, E; Cartwright, T H; Das, A; de Bono, J S; Feit, K; Loesch, D M; Maroto, J P; Molife, L R; Petrylak, D P et al.
DOI: 10.1093/annonc/mdr380

Publications

Publications searcher

Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.

Perioperative use of prothrombin complex concentrates.

Perioperative use of prothrombin complex concentrates.

Persistent Angina Pectoris, Cardiac Mortality and Myocardial Infarction During a 12 Year Follow-Up in 273 Variant Angina Patients Without Significant Fixed Coronary Stenosis.

Persistent Angina Pectoris, Cardiac Mortality and Myocardial Infarction During a 12 Year Follow-Up in 273 Variant Angina Patients Without Significant Fixed Coronary Stenosis.

Personality profile of adult ADHD: The alternative five factor model.

Personality profile of adult ADHD: The alternative five factor model.

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Phase 1 Pharmacokinetic/Pharmacodynamic Study of MLN8237 - An Investigational, Oral, Selective Aurora A Kinase Inhibitor - In Patients With Advanced Solid Tumors.

Phase 1 Pharmacokinetic/Pharmacodynamic Study of MLN8237 - An Investigational, Oral, Selective Aurora A Kinase Inhibitor - In Patients With Advanced Solid Tumors.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors.

Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy.

Patronage:

Collaborating:

Accreditations: